A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected in the Morning or Evening in Patients With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period
A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected in the Morning or Evening in Patients With Type 1 Diabetes Mellitus With a 6-month Safety Extension Period
Primary Objective:
Secondary Objective:
The maximum study duration was up to approximately 54 weeks per participants:
Inclusion criteria:
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Viljandimaa, 71024, Estonia
Ise-Shi, Japan
Karatsu-Shi, Japan
Kitakyushu-Shi, Japan
Matsumoto-Shi, Japan
Tomishiro, Japan